Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Breast 2

Conditions

Small Cell Lung Carcinoma 2Breast Neoplasms 2Rhabdoid Tumor 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × MLN 8237 × 1 year × Clear all
NCT06095505 2026-06-05

ALISCA-Lung1

Puma Biotechnology, Inc.

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02114229 2026-03-17

SJATRT

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
125 enrolled

Rhabdoid Tumor

NCT07465757 2026-03-12

ALISCA-Lung2

Puma Biotechnology, Inc.

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Mayo Clinic

Phase 2 Completed
96 enrolled 34 charts
Breast

Breast Neoplasms

NCT06369285 2025-12-10

ALISCA-Breast1

Puma Biotechnology, Inc.

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡